Clinical Trial Update: A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India [Phase 4]

View source ↗

Summary

ClinicalTrials.gov update for a Phase 4 study evaluating the safety and tolerability of a fixed-dose combination of nivolumab and relatlimab in untreated, unres…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Relatlimab (relatlimab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Untreated Melanoma, Unresectable Melanoma | Phase 4 | Status: NOT_YET_RECRUITING